Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2016 06:30 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo Reports Third Quarter 2016 Financial Results

Results Driven by 73% Growth in Revenue GAAP EPS Growth of 12%; Adjusted EPS Growth of 58% Company Raises 2016 Guidance and Provides Preliminary 2017 Guidance Announces Settlement with Dr....
June 15, 2015 16:02 ET | Source: Sucampo Pharmaceuticals Inc

China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA(R) (lubiprostone)

BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration...
May 15, 2015 16:02 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week

BETHESDA, Md., May 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be...
May 11, 2015 16:02 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo and Harbin Gloria Pharmaceuticals Enter Into Licensing Agreement for AMITIZA(R) (lubiprostone) in China

BETHESDA, Md., May 11, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that it entered into an exclusive license,...
February 18, 2015 06:45 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2014 Earnings Call

BETHESDA, Md., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and...
January 30, 2015 06:45 ET | Source: Sucampo Pharmaceuticals Inc

AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries

BETHESDA, Md., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the successful completion of the European...
December 30, 2014 17:00 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo Announces Acceptance of New Drug Submission for AMITIZA(R) (lubiprostone) by Health Canada

BETHESDA, Md., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Health Canada has accepted the...
November 06, 2014 06:45 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo Announces Third Quarter 2014 Financial Results

Strong Revenue and Sales Growth for AMITIZA Raises 2014 Earnings Guidance, Excluding Special Items CEO Peter Greenleaf to Provide Update on Significant Progress Against Strategic Plan...
October 21, 2014 18:00 ET | Source: Sucampo Pharmaceuticals Inc

Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)

BETHESDA, Md., October 21, 2014 and OSAKA, Japan, October 22, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, and Takeda...
October 14, 2014 06:45 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda

BETHESDA, Md., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it signed on October 9, 2014 an...